Pfizer's cancer drug combo improves overall survival in late-stage study
Pfizer's combination of Talzenna and Xtandi has shown a notable improvement in overall survival rates for patients with metastatic castration-resistant prostate cancer (mCRPC) in a late-stage study. This combination works regardless of genetic mutations, offering a significant advancement over using Xtandi alone. Pfizer aims to update Talzenna's label globally based on these promising results.
Comment / Reply From
You May Also Like
Popular Posts
Newsletter
Subscribe to our mailing list to get the new updates!